Enlivex Therapeutics Ltd. (ENLV) Research

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Market snapshot

Symbol
ENLV
Price
$0.62
Day change
+0.60%
Market cap
$15.1M
P/E ratio
0.02x
52-week range
0.6106-2.1
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$15.00

Peer companies

  • CollPlant Biotechnologies Ltd. (CLGN)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • CytoMed Therapeutics Limited (GDTC)
  • Lisata Therapeutics, Inc. (LSTA)
  • MetaVia Inc. (MTVA)
  • NuCana plc (NCNA)
  • NeuroSense Therapeutics Ltd. (NRSN)
  • NeurAxis, Inc. (NRXS)

Recent insider activity

  • Hershkovitz Oren — trade (0 shares) on 2026-03-18
  • Hershkovitz Oren — trade (150000 shares) on 2023-11-16
  • Hershkovitz Oren — trade (60000 shares) on 2025-11-24
  • Shlosberger Shachar — trade (0 shares) on 2026-03-18
  • Shlosberger Shachar — trade (1452 shares) on 2021-03-07

Open Enlivex Therapeutics Ltd. (ENLV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.